Martin Urbicain
Overview
Explore the profile of Martin Urbicain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu X, Sarabia S, Urbicain M, Somvanshi S, Patel R, Tran T, et al.
bioRxiv
. 2025 Jan;
PMID: 39763896
Most malignant hepatocellular tumors in children are classified as either hepatoblastoma (HB) or hepatocellular carcinoma (HCC), but some tumors demonstrate features of both HB and HCC. These tumors have been...
2.
An indocyanine green-based liquid biopsy test for circulating tumor cells for pediatric liver cancer
Espinoza A, Kureti P, Patel R, Do S, Govindu S, Armbruster B, et al.
Hepatol Commun
. 2024 May;
8(6).
PMID: 38727682
Background: Hepatoblastoma and HCC are the most common malignant hepatocellular tumors seen in children. The aim of this study was to develop a liquid biopsy test for circulating tumor cells...
3.
Patel K, Espinoza A, Urbicain M, Patel R, Major A, Sarabia S, et al.
Pathol Res Pract
. 2024 Feb;
255:155163.
PMID: 38394806
Advances in targeted therapies for pediatric hepatocellular tumors have been limited due to a paucity of clinically relevant models. Establishment and validation of intrahepatic patient-derived xenograft (PDX) models would help...
4.
Espinoza A, Patel R, Patel K, Badachhape A, Whitlock R, Srivastava R, et al.
J Hepatol
. 2024 Jan;
80(4):610-621.
PMID: 38242326
Background & Aims: Patients with metastatic, treatment-refractory, and relapsed hepatoblastoma (HB) have survival rates of less than 50% due to limited treatment options. To develop new therapeutic strategies for these...
5.
Espinoza A, Patel K, Shetty P, Whitlock R, Sumazin P, Yu X, et al.
Cancer Med
. 2023 Nov;
12(23):21270-21278.
PMID: 37962078
Objective: Hepatoblastoma (HB) is the most common primary hepatic malignancy in childhood. Relapse occurs in more than 50% of high-risk patients with a high mortality due to ineffective salvage therapies....
6.
Chen Wongworawat Y, Sarabia S, Urbicain M, Francalanci P, Sumazin P, Alaggio R, et al.
Pediatr Dev Pathol
. 2023 Oct;
27(2):169-175.
PMID: 37903123
Hepatoblastomas (HB) are embryonal tumors with quiet genomes diagnosed mostly in children under 3 years of age and often cured by surgical resection and chemotherapy. However, a subset of HBs...
7.
An indocyanine green-based liquid biopsy test for circulating tumor cells for pediatric liver cancer
Espinoza A, Kureti P, Patel R, Govindu S, Armbruster B, Urbicain M, et al.
bioRxiv
. 2023 Jul;
PMID: 37461615
Background And Aims: Hepatoblastoma (HB) and hepatocellular carcinoma (HCC) are the most common malignant hepatocellular tumors seen in children. The aim of this work was to develop a liquid biopsy...
8.
Sumazin P, Peters T, Sarabia S, Kim H, Urbicain M, Hollingsworth E, et al.
J Hepatol
. 2022 May;
77(4):1026-1037.
PMID: 35577029
Background & Aims: Hepatoblastoma (HB) and hepatocellular carcinoma (HCC) are the predominant liver cancers in children, though their respective treatment options and associated outcomes differ dramatically. Risk stratification using a...